Biofrontera AG (FRA:B8FK) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:B8FK Biofrontera AG FRA:B8FK
62 GF Score
Price €2.54
GF Value €2.19
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Biofrontera AG Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:B8FK
62GF Score
Biofrontera AG FRA:B8FK
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biofrontera AG (FRA:B8FK) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera AG stock appears to be overvalued. The current stock price of €2.54 is trading 16% above its estimated GF Value™ of €2.19. GuruFocus considers Biofrontera AG to be Modestly Overvalued.

Key valuation signals for FRA:B8FK:

  • Short Ratio:
  • GF Value™: €2.19 vs. price of €2.54 (16% above fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the FRA:B8FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biofrontera AG Business Description

Other Exchanges 0DOL:UKB8FK:Germany
Address Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
62GF Score

Get the complete analysis for FRA:B8FK

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.54
Price
€2.19
GF Value